MYTHIC THERAPEUTICS
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics. The company is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Their technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets.
MYTHIC THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Life Science Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.mythictx.com
Total Employee:
11+
Status:
Active
Total Funding:
126.6 M USD
Technology used in webpage:
Google Apps For Business
Similar Organizations
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Morphic Therapeutic
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series B - Mythic Therapeutics
Venrock
Venrock investment in Series B - Mythic Therapeutics
First Round Capital
First Round Capital investment in Series B - Mythic Therapeutics
Foresite Capital
Foresite Capital investment in Series B - Mythic Therapeutics
OMX Ventures
OMX Ventures investment in Series B - Mythic Therapeutics
Refactor Capital
Refactor Capital investment in Series B - Mythic Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series B - Mythic Therapeutics
Highside Capital Management
Highside Capital Management investment in Series B - Mythic Therapeutics
Viking Global Investors
Viking Global Investors investment in Series B - Mythic Therapeutics
Lifeforce Capital
Lifeforce Capital investment in Series B - Mythic Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-23 | Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer |
Official Site Inspections
http://www.mythictx.com Semrush global rank: 4.56 M Semrush visits lastest month: 2.28 K
- Host name: 35.92.212.35.bc.googleusercontent.com
- IP address: 35.212.92.35
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Mythic Therapeutics"
Mythic Therapeutics - Building smarter and safer antibody-drug …
Mythic’s innovative FateControlâ„¢ technology increases ADC uptake in cancerous cells while avoiding payload release in normal cells. This allows us to dramatically increase efficacy for a …See details»
About Us - Mythic Therapeutics
Check out the presentations the team at Mythic Therapeutics has given, as well as published articles.See details»
Mythic Therapeutics, Inc. | LinkedIn
Mythic Therapeutics is a product-platform company that is pioneering a powerful new approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based...See details»
Mythic Therapeutics - Crunchbase Company Profile
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics. The company is pioneering a powerful protein engineering-focused approach to improving the effectiveness of …See details»
Clinical Program - Mythic Therapeutics
Mythic Therapeutics is now enrolling in Phase 1 clinical trial KisMET to evaluate the safety and efficacy of MTYX-011 in NSCLC.See details»
Mythic Therapeutics - Overview, News & Similar companies
Apr 7, 2024 · View Mythic Therapeutics (www.mythictx.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Associate Director, Clinical Operations - Mythic Therapeutics
Influences: Highly credible with various stakeholder group (internal employees up-down and across the organization, external collaborators, partners, and vendors and with site teams and …See details»
ASCO ABSTRACT TPS9147 - American Society of Clinical Oncology
MYTX-011, an investigational cMET-targeting ADC, leverages Mythic’s innovative FateControlTM technology, which allows ADCs to actively navigate inside of cells to potentially increase …See details»
Mythic Therapeutics Receives FDA Fast Track …
Sep 26, 2023 · MYTX-011, an investigational cMET-targeting ADC, leverages Mythic’s innovative FateControlâ„¢ technology which is designed to allow ADCs to actively navigate inside of cells, potentially...See details»
Mythic Therapeutics Receives FDA Fast Track Designation for
Sep 26, 2023 · MYTX-011, an investigational cMET-targeting ADC, leverages Mythic’s innovative FateControlâ„¢ technology which is designed to allow ADCs to actively navigate inside of cells, …See details»
Mythic Therapeutics Announces Publication of Preclinical Data ...
Apr 30, 2024 · MYTX-011, an investigational cMET-targeting antibody-drug conjugate (ADC), leverages Mythic’s innovative FateControlâ„¢ technology, which allows ADCs to actively …See details»
Mythic Therapeutics Launches with New Approach to Improving …
Dec 15, 2021 · Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy.See details»
Our Science - Mythic Therapeutics
At Mythic Therapeutics, our scientific approach focuses on how ADCs and their targets are trafficked through cells.See details»
Mythic Therapeutics Presents Preclinical Data on MYTX-011, an ...
MYTX-011 is efficacious against cMET-expressing xenograft models derived from multiple solid tumor types including gastric, esophageal, and head and neck cancers.See details»
Mythic Therapeutics Presents Initial Dose Escalation Data from …
Jun 3, 2024 · "The initial dose escalation results from our ongoing Phase 1 KisMET-01 study, coupled with the previously presented preclinical data are encouraging and underscore MYTX …See details»
Mythic Therapeutics Announces First Subject Dosed in Phase 1
Apr 4, 2023 · MYTX-011 is a cMET-targeting ADC being investigated for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC).See details»
Mythic Therapeutics to Present Data from Phase 1 KisMET-01 …
May 23, 2024 · MYTX-011, an investigational cMET-targeting ADC, leverages Mythic’s innovative FateControlâ„¢ technology which is designed to allow ADCs to actively navigate inside of cells, …See details»
Clinical Program - Original - Mythic Therapeutics
Mythic Therapeutics is now enrolling in Phase 1 clinical trial KisMET to evaluate the safety and efficacy of MTYX-011 in NSCLC.See details»
Mythic Therapeutics Announces Publication of Preclinical Data ...
Apr 30, 2024 · MYTX-011, an investigational cMET-targeting antibody-drug conjugate (ADC), leverages Mythic’s innovative FateControlâ„¢ technology, which allows ADCs to actively …See details»
Mythic Therapeutics Presents Preclinical Data on Investigational …
Apr 18, 2023 · Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy.See details»